 Home > Active Ingredient News > Drugs Articles > Centralized procurement is exchanged for price, and CSPC Pharmaceutical Group, Qilu Pharmaceutical, and Jingxin Pharmaceutical are aiming at this golden track

Centralized procurement is exchanged for price, and CSPC Pharmaceutical Group, Qilu Pharmaceutical, and Jingxin Pharmaceutical are aiming at this golden track

 Last Update: 2023-02-01
 Source: Internet
 Author: User

Tags

anti gravity water

anti fouling paint

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Authoritative data shows that there are now more than 3 million Parkinson's patients
in China.
Experts from the World Health Organization predict that by 2030, there will be 5 million
Parkinson's disease patients in China.

There are now more than 3 million Parkinson's patients
in our country.
In 2030, there will be 5 million
Parkinson's disease patients in China.

With the liberalization of domestic epidemic prevention and control policies, China's elderly chronic disease population is facing a more severe test
.
Parkinson's disease, as a chronic disease that mostly occurs in the elderly group, is the most common neurodegenerative disease in the world except Alzheimer's disease, and has become the third major killer of physical and mental health of middle-aged and elderly people after cancer and cardiovascular and cerebrovascular diseases
.

In China's anti-Parkinson's market, foreign original pharmaceutical companies such as Roche and Boehringer Engelheim occupy most of the market share, and local enterprises led by CSPC Pharmaceutical Group, Qilu Pharmaceutical and Jingxin Pharmaceutical are gradually making efforts
in the market driven by centralized procurement.

Foreign original pharmaceutical companies such as Roche and Boehringer Engelheim occupy most of the market share, and local enterprises led by CSPC Pharmaceutical Group, Qilu Pharmaceutical and Jingxin Pharmaceutical are gradually making efforts
in the market driven by centralized procurement.
Jingxin Pharmaceutical

01 Parkinson's drug market continues to expand, hospitals decline 6% year-on-year, retail market up 11%

From the demand side, China's Parkinson's patients account for a high proportion of the world, and the number of Parkinson's patients in China will continue to increase
in the future.
The "Parkinson's Disease Treatment Guidelines" issued by the Chinese Medical Association mentions that China 65 The prevalence of people over the age of 1.
7% will increase from 1.
99 million in 2005 to 5 million in 2030, accounting for almost half
of the global Parkinson's disease cases.

Number of elderly people aged 60 and above in China and their proportion in the total population of the country (2012-2021)

Data source: National Bureau of Statistics, Zhongkang Retail Market Research Center

From the supply side, national centralized procurement has significantly improved
the accessibility of drugs.
The fourth batch of national centralized procurement began to be implemented in 2021Q2, pramipexole as one of the mainstream drugs for the treatment of Parkinson's disease, the only related drugs to enter centralized procurement, anti-Parkinson's market has ushered in a pattern change
.

According to Zhongkang CMH data, in 2021, the scale of the anti-Parkinson's market of the two major channels in China (hospital channels and retail channels) will reach 2.
9 billion yuan, with a compound growth rate of 9%, and the volume and price will jointly promote the growth
of category scale.
In 2021, the number of sales of the two major channels in the country increased by 8% year-on-year, of which the hospital channel was the main battlefield of centralized procurement, and the effect of price for volume was obvious, and the number of sales films increased by 10%
year-on-year.

In 2021, the scale of the anti-Parkinson's market of the two major channels in China will reach 2.
9 billion yuan, with a compound growth rate of 9%, and the volume and price will rise together to jointly promote the growth
of category scale.
Among them, the hospital channel is the main battlefield of centralized procurement, and the effect of exchanging price for volume is obvious, and the number of sales films increased by 10%
year-on-year.

However, it is worth noting that since the landing of centralized procurement in 2021Q2, the sales of the hospital market have fallen by 6% year-on-year, while retail channel sales have grown rapidly, increasing by 11% year-on-year, please refer to the figure below
for details.

The two major channels - the national - anti-Parkinson's market sales (billion yuan) trend & growth rate performance

Data source: Zhongkang CMH Zhongkang CMH Hospital data monitoring scope: the national secondary and above public hospital drug market

As the supply side of the rapidly developing drug market, the B2C channel has brought more development space
to the anti-Parkinson's market.
The outbreak of the epidemic in early 2020 has promoted the process
of selling prescription drugs online.
According to Zhongkang CMH's B2C data, since the opening of prescription drugs online in April 2020, The scale of the anti-Parkinson's market continued to increase, maintaining rapid monthly growth
year-on-year.

According to Zhongkang CMH's B2C data, since the opening of prescription drugs online in April 2020, The scale of the anti-Parkinson's market continued to increase, maintaining rapid monthly growth
year-on-year.

B2C-Anti-Parkinson's Market Sales Trends

Source: Zhongkang CMH

02 The domestic variety concentration is high, and the growth of compound levodopa leads the market

The world's top five Parkinson's drugs are rotigotine, rasagiline, levabidopa, dopaserazide and droxidopa, occupying 89% of the market share
of the anti-Parkinson's market.
According to Zhongkang CMH data, in the anti-Parkinson's market of China's two major channels, dopaserazide and pramipexole ranked first and second, accounting for 70% of the market share, and the concentration of varieties is extremely high
.

According to Zhongkang CMH data, in the anti-Parkinson's market of China's two major channels, dopaserazide and pramipexole ranked first and second, accounting for 70% of the market share, and the concentration of varieties is extremely high
.

The Chinese Guidelines for the Treatment of Parkinson's Disease (Fourth Edition) pointed out that the drug treatment of early Parkinson's disease includes compound levodopa, dopamine receptor agonists (DAs), MAO-BI, catechol-O-methyltransferase inhibitors (COMTI), anticholinergics and antiglutamatergic drugs
.

As the "gold standard" for Parkinson's disease, compound levodopa is the most effective symptomatic treatment drug
in the treatment of Parkinson's disease.
Among them, mainly represented by dopaserazide, accounting for 38% of the sales share, the number of sales pieces increased by 10%, driving sales growth and leading the market
.
After Pramipexole entered centralized procurement, the price fell significantly, and the number of sales pieces increased by 22% year-on-year in exchange for volume
.

After Pramipexole entered centralized procurement, the price fell significantly, and the number of sales pieces increased by 22% year-on-year in exchange for volume
.

From the perspective of the number of sales pieces, trihephenidyl and amantadine accounted for 27% and 6% of the sales piece share, ranking second and fourth in the market, and together with dopaserazide and pramipexole occupied nearly ninety percent of the sales piece market
.
Although the number of dihexyphenidine and amantadine sales is dominant, its price is low (the price of each tablet is 0.
2 yuan, 0.
1 yuan), so that its sales account for a relatively small
proportion.
Diphenhydridyl is effective in improving tremor, but long-term use can have the side effects
of damaging memory and even leading to dementia.

Although the number of dihexyphenidine and amantadine sales is dominant, its price is low (the price of each tablet is 0.
2 yuan, 0.
1 yuan), so that its sales account for a relatively small
proportion.

Competitive Pattern of Two Channels - National - Anti-Parkinson's Market (2021)

Source: Zhongkang CMH

Dopaserazide and pramipexole as mainstream drugs for the treatment of Parkinson's disease account for seventy percent of the overall market
.
From the following TOP brand performance, it can be seen that Roche Medoba, which is an imported original drug, and Senforo, which is Boehringer Ingelheim, are still in an absolute leading position
.

Roche Medopa, which is an imported original drug, and Senforo of Boehringer Ingelheim are still in an absolute leading position
.

Two major channels - national - dopaxazide / pramipexole - TOP brand competition pattern (2021)

Source: Zhongkang CMH

Roche and Boehringer Ingelheim, as world-class pharmaceutical giants, disclosed that Roche's sales in 2021 reached US$65.
8 billion, an increase of 8% year-on-year, of which pharmaceutical business sales increased by 1%
year-on-year.
In 2021, Boehringer Ingelheim's sales in 2021 reached $22.
3 billion, up 7.
5%
year-on-year.
Among them, the biopharmaceutical business increased by 9.
5%
year-on-year.

03 Domestic substitution in the in-hospital market accelerated

Sales of original research drugs fell 44% year-on-year, and in the anti-Parkinson's market, imported original drugs accounted for ninety percent of the sales share
before the start of the fourth batch of centralized procurement.
With the implementation of the fourth batch of national centralized procurement in 2021Q2, in the pramipexole market, the winning generic drugs led by Sopule (Jingxin Pharmaceutical), Enxi (CSPC Pharmaceutical Group) and Qi Shuning (Qilu Pharmaceutical) led the share of generic drugs to increase rapidly, breaking the monopoly market of original drugs, accelerating the speed of replacing original drugs with generic drugs, and helping local enterprises expand the anti-Parkinson's market
.

The sales of original drugs fell by 44% year-on-year, and the winning generic drugs led by Sopule (Jingxin Pharmaceutical), Enxi (CSPC Pharmaceutical Group), and Qi Shuning (Qilu Pharmaceutical) led the rapid increase in the share of generic drugs.

Nationwide - two major channels - original drugs/generic drug sales proportion

Source: Zhongkang CMH

As the main battlefield of the hospital channel, the share of sales of pramipexole generic drugs continued to increase, surpassing the unbid original research drug Senforo in 2021Q3, and by the end of 2021, the winning generic drug had occupied 81% of the sales share in the hospital channel
.
In 2021, the sales of pramipexole winning the bid generic drug in the hospital channel increased by 426% year-on-year, and the number of sales tablets showed a rapid growth of four digits, and the unqualified original drug Senforo was affected by the generic drug, and the sales fell by 44%
year-on-year.

By the end of 2021, the winning generic drug had accounted for 81% of the sales volume share in the hospital channel
.
The sales of generic drugs in the hospital channel increased by 426% year-on-year, and the original drug Senforo that did not win the bid was affected by generic drugs, and its sales fell by 44%
year-on-year.

National - two major channels - pramipexole - unwon original research drug/bid generic drug market performance

Source: Zhongkang CMH

According to the implementation of centralized procurement, the procurement margin in the pramipexole market is basically occupied by the original research drug Senforo, and the retail channel and B2C channel have become the key markets
for the development of the original research drug.
After 2021Q2, the sales scale of pramipexole original drugs in retail channels and B2C channels continued to increase, and the scale of winning generic drugs increased slightly, but it has not affected the monopoly
of original drugs in the out-of-hospital market.

After 2021Q2, the sales scale of pramipexole original drugs in retail channels and B2C channels continued to increase, and the scale of winning generic drugs increased slightly, but it has not affected the monopoly
of original drugs in the out-of-hospital market.

B2C channel - pramipexole - unwon original drug / winning generic drug sales trend (million yuan).

Data source: Zhongkang CMH Pa

Kingson's disease is a major disease that affects human health and life, and with the aging of the population, the demand of society increases
.
The rapid development of B2C channels and the normalization of national centralized procurement have promoted drug accessibility, enabling patients to use high-quality and affordable drugs
.
The market share of domestic generic drugs in the hospital market has gradually increased, but the competitiveness in the out-of-hospital market needs to be strengthened
.
At present, a number of foreign drugs for the treatment of Parkinson's have not yet been introduced into China, and with the continuous acceleration of the domestic approval process for imported drugs, the domestic Parkinson's market is expected to further develop in
the future.

The market share of domestic generic drugs in the hospital market has gradually increased, but the competitiveness in the out-of-hospital market needs to be strengthened
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.